Form D · Venture Capital Fund

Redmile Biopharma Investments II, L.P.

San Francisco, CA · CIK 0001772230

Offering snapshot reported Mar 5, 2020 · SEC filing

Reported sold
$675M
Offering amount: $675M
Investors reported
137
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 22, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$338M$675MMar 29, 2019: $331,350,000.00Mar 29, 2019Mar 5, 2020: $675,420,000.00Mar 5, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$331,350,000 → $675,420,000
  • Reported investors27 → 137

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 5, 2020Amendment$675,420,000$344,070,000vs Mar 29, 2019137SEC filing
Mar 29, 2019Initial$331,350,000No comparison27SEC filing

Offering details

Securities
Pooled investment fund
Exemptions
06b, 3C, 3C.7
Duration over one year
No
Business combination
No
Sales commissions
$7.3M
Finders' fees
$0
Form D file number
021-335974

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
J.P. Morgan Securities LLC79
Hollister Associates, LLC173366

Source: Form D, filed Mar 5, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

REDMILE BIOPHARMA INVESTMENTS II, L.P.

Investment adviser: REDMILE GROUP, LLC

Gross asset value
$661M
Beneficial owners
140
ADV minimum commitment
$5M

Reported in Form ADV on Aug 28, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator ALTER DOMUS (US) LLC CHICAGO, Illinois, United States Investor statements: Yes (provided to all investors) Related to adviser: No
Auditor ERNST & YOUNG LLP SAN FRANCISCO, California, United States
Custodian JP MORGAN CHASE BANK, N.A. NEW YORK, New York, United States Related to adviser: No
Custodian MORGAN STANLEY & CO. LLC SAN FRANCISCO, California, United States Related to adviser: No
Prime broker MORGAN STANLEY & CO. LLC SAN FRANCISCO, California, United States
Provider details
Annual audit
Yes
Prime brokers
Yes
Custodians
Yes
Administrator other than the adviser
Yes
External marketing
No

ERNST & YOUNG LLP
PCAOB 42

JP MORGAN CHASE BANK, N.A.
LEI 7H6GLXDRUGQFU57RNE97

MORGAN STANLEY & CO. LLC
SEC 8-15869

MORGAN STANLEY & CO. LLC
CRD 8209 · SEC 8-15869

Filing source

Form ADV 2125340 · Aug 28, 2026 · Schedule D 7.B.(1), fund 805-9153149946

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jeremy Green Executive
Mike Lee Executive
Amrit Nagpal Executive
N/A Redmile Biopharma Investments Ii (Gp), Llc Promoter
N/A Redmile Group, Llc Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:
Letterman Digital Arts Center One Letterman Drive, Suite D3 300
San Francisco, CA, 94129